Research programme: DNA encoded monoclonal antibodies - Inovio Pharmaceuticals/Wistar Institute
Latest Information Update: 05 May 2021
At a glance
- Originator Inovio Pharmaceuticals; Wistar Institute
- Developer AstraZeneca; Inovio Pharmaceuticals; Wistar Institute
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants; Natural killer cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 31 Dec 2020 Inovio Pharmaceuticals receives grant from the US Defense Advanced Research Projects Agency (DARPA) for INO A002 development in COVID-2019 infections
- 31 Dec 2020 Preclinical trials in COVID-2019 infections (Prevention) in USA (IM) prior to December 2020
- 31 Dec 2020 Preclinical trials in COVID-2019 infections in USA (IM) prior to December 2020